Caicedo-Rusca L, Sabogal-Niño A, Serrano-Ardila O, Villegas-Otálora J, Botero-Osorio V, Agudelo-Constante M, Lotero-Díaz V, Dávalos-Pérez D, Manzi-Tarapues E, Aristizabal-Bolaños AM, Echeverri-Junca G

Language: Spanish
References: 22
Page: 18-28
PDF size: 1209.97 Kb.

ABSTRACT

Introduction: Hepatoblastoma is the most common primary liver tumor in children and usually is diagnosed during the first three years of life. Overall survival has increased 50%, this because of chemotherapeutic schemes and expertise surgery centers. Objectives: Evaluate biodemographic characteristics, diagnosis, treatment, monitoring and survival of patients with hepatoblastoma. Material and methods: Retrospective analysis n: 17 patients diagnosed with hepatoblastoma, from medical records of 2011-2014. Included: 1) demographic variables and prenatal history; 2) diagnostic tests and histological classification; 3) surgical and/or chemotherapy treatment and complications; 4) outcome and survival. PRETEXT-POSTEXT classification, staging risk (SIOPEL), surgical resection classification (Brisbane terminology) and modified Clavien classification. Results: 20% showed low birth weight (≤ 2,499 g). Average age at diagnosis was 19.4 months (range 7-36 months). The biggest cause of medical consultation was abdominal mass. All patients had high levels of alpha-fetoprotein (AFP) and an imaging study; laparoscopic biopsy was performed at 52.94%. All patient received neoadjuvant and adjuvant chemotherapy; 56.2% were classified with standard risk. Groups: liver transplantation n = 8; radical resection n = 8; one patient was excluded (cause: metastases). There were no complications related to surgery; 37.5% were grade-I in modified Clavien classification. Disease-free survival (3-years): 100% liver resection and 60% liver transplant. Conclusions: The management of the disease should be performed early in referral centers by multidisciplinary groups. There by increasing the probability of survival of patients.

REFERENCES

1. Finegold MJ, Lopez-Terrada DH, Bowen J, Washington MK, Qualman SJ; College of American Pathologists. Protocol for the examination of specimens from pediatric patients with hepatoblastoma. Arch Pathol Lab Med. 2007; 131 (4): 520-529.

2. Kitanovski L, Ovcak Z, Jazbec J. Multifocal hepatoblastoma in a 6-month-old girl with trisomy 18: a case report. J Med Case Rep. 2009; 3: 8319.

3. Meyers RL, Tiao G, de Ville de Goyet J, Superina R, Aronson DC. Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr. 2014; 26 (1): 29-36.

4. Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014; 26 (1): 19-28.

5. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer. 2012; 59 (5): 776-779.

6. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

7. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer. 2008; 112 (2): 416-432.

8. Maibach R, Roebuck D, Brugieres L, Capra M, Brock P, Dall’Igna P et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. Eur J Cancer. 2012; 48 (10): 1543-1549.

9. Herzog CE, Andrassy RJ, Eftekhari F. Childhood cancers: hepatoblastoma. Oncologist. 2000; 5 (6): 445-453.

10. Kremer N, Walther AE, Tiao GM. Management of hepatoblastoma: an update. Curr Opin Pediatr. 2014; 26 (3): 362-369.

11. Hishiki T. Current therapeutic strategies for childhood hepatic tumors: surgical and interventional treatments for hepatoblastoma. Int J Clin Oncol. 2013; 18 (6): 962-968.

12. Haeberle B, Schweinitz DV. Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies. Front Biosci (Elite Ed). 2012; 4: 493-498.

13. Malogolowkin MH, Katzenstein HM, Krailo M, Meyers RL. Treatment of hepatoblastoma: the North American cooperative group experience. Front Biosci (Elite Ed). 2012; 4: 1717-1723.

14. Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville de Goyet J, Gauthier F et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2007; 37 (2): 123-132; quiz 249-50.

15. Watanabe K. Current chemotherapeutic approaches for hepatoblastoma. Int J Clin Oncol. 2013; 18 (6): 955-961.

16. Manterola DC, Moraga CJ, Urrutia VS. Morbilidad postoperatoria en pacientes con hidatidosis hepática no complicada: Utilización de una propuesta de clasificación de complicaciones. Rev Chil Cir. 2010; 62 (4): 362-368.

17. Rodriguez-Galindo C, Krailo M, Frazier L, Chintagumpala M, Amatruda J, Katzenstein H et al. Children’s Oncology Group’s 2013 blueprint for research: rare tumors. Pediatr Blood Cancer. 2013; 60 (6): 1016-1021.

18. Herrera JM, Rossi FR, Harris DP, Wietstruck PA, Barriga CF. Progresos en el tratamiento y seguimiento de hepatoblastoma: Análisis de una serie de 9 niños. Rev Chil Pediatr. 2002; 73 (1): 43-50.

19. Medscape. Pediatric hepatoblastoma. 2015. Available in: http://emedicine.medscape.com/article/986802-overview.

20. Ovchinsky N, Moreira RK, Lefkowitch JH, Lavine JE. Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol. 2012; 19 (4): 250-262.

21. Varela-Fascinetto G, Dávila-Pérez R, Hernández-Plata A, Castañeda-Martínez P, Fuentes-García V, Nieto-Zermeño J. Trasplante hepático en niños. Rev. Invest Clín. 2005; 57 (2): 273-282.

22. Serrano OJ, Villegas JI, Echeverri GJ, Posada JG, Mesa L, Schweineberg J et al. Trasplante simultáneo de riñón y páncreas en pacientes con diabetes mellitus de tipo 1, Clínica Fundación Valle del Lili, Cali, 2001-2013. Rev Colomb Cir. 2014; 29 (1): 32-41.